Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Helix BioPharma's operating assets for the quarter that ended in Apr. 2026 was $13.48 Mil. Helix BioPharma's operating liabilities for the quarter that ended in Apr. 2026 was $4.61 Mil. Helix BioPharma's Total Assets for the quarter that ended in Jan. 2026 was $13.45 Mil. Therefore, Helix BioPharma's scaled net operating assets (SNOA) for the quarter that ended in Apr. 2026 was 0.66.
Helix BioPharma Scaled Net Operating Assets Related Terms
Helix BioPharma Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Helix BioPharma's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBPCF vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Helix BioPharma's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helix BioPharma Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helix BioPharma's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Helix BioPharma's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.66 mean?
Helix BioPharma (HBPCF) has a Scaled Net Operating Assets of 0.66 as of Apr. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Helix BioPharma and its competitors.
Is Helix BioPharma's Scaled Net Operating Assets too high?
Helix BioPharma's current Scaled Net Operating Assets is 0.66. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's Scaled Net Operating Assets compare to VRTX and REGN?
Helix BioPharma's Scaled Net Operating Assets of 0.66 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Helix BioPharma and its competitors. Helix BioPharma's current Scaled Net Operating Assets is 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current Scaled Net Operating Assets of 0.66. The current Scaled Net Operating Assets is 0.66. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current Scaled Net Operating Assets is 0.66 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score
Get the complete analysis for HBPCF
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBPCF has been successfully added to your 
